Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Lung Neoplasms 12Small Cell Lung Carcinoma 5Nonsquamous Non-Small Cell Lung Cancer 2Neoplasms 2Carcinoma 2Advanced Lung Cancer 2Thoracic Neoplasms 1Stomach Neoplasms 1Squamous Non-Small Cell Lung Cancer SqNSCLC 1Squamous NSCLC 1Squamous Cell Non-small Cell Lung Cancer 1Small Cell Lung Cancer Extensive Stage 1SCLC 1Respiratory Tract Diseases 1Resectable Non-small Cell Lung Cancer 1Resectable NSCLC 1Radiation Pneumonitis 1Osteosarcoma 1Non-small Cell Lung Cancer Metastatic 1Non-Squamous Non-Small Cell Lung Cancer 1NSCLC 1Multiple Primary Lung Cancer 1Lung Diseases 1Locally Advanced Non-Small Cell Lung Cancer 1IIIA Stage Non-small Cell Lung Cancer 1High-Risk Resectable NSCLC 1Brain Neoplasms 1Advanced Non-squamous Non-Small-Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1

Interventions

Carboplatin 18Pemetrexed 10Paclitaxel 6pembrolizumab 5Nivolumab 5Cisplatin 5Gemcitabine 4osimertinib 3entinostat 3camrelizumab 3atezolizumab 3Erlotinib Hydrochloride 3selpercatinib 2pralsetinib 2durvalumab 2apatinib 2Vinorelbine 2Surveys and Questionnaires 2One-Lung Ventilation 2Ipilimumab 2Drug Delivery Systems 2Docetaxel 2Bronchoscopy 2Bevacizumab 2130-nm albumin-bound paclitaxel 2zipalertinib 1zimberelimab 1toripalimab 1taletrectinib 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Diseases × sintilimab × Thoracic × Clear all
NCT04371796 2020-05-01

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Sichuan Cancer Hospital and Research Institute

Phase 2 Unknown
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡